The document discusses the advantages of an integrated ERP solution for the pharmaceutical industry using Microsoft Dynamics AX. It summarizes that AX for Pharma 2012 is fully compliant with various regulatory requirements, enforces operating procedures and work practices, integrates key functionality like LIMS and plant maintenance, and supports a wide range of workflows to reduce costs and ensure consistency and compliance. The approach aims to significantly reduce implementation costs through a single team and minimizing customizations.
Modern BioManufacturing: Single-Use Technologies in Configurable, Prefabricat...MilliporeSigma
A co-webinar describing a solution to biopharma's challenge of rapidly and rationally expanding capacity by employing single-use technologies, a templated process train, and pre-fabricated mobile/modular cleanrooms.
Biopharmaceutical companies on the verge of investing into manufacturing or facilities expansion face many questions and challenges. Speed, agility, and flexibility are becoming more critical to executing their changing production and distribution strategies. Platform facility designs which integrate the latest procss technologies wthin innovative pre-fabricated cleanrooms are critical for addressing the trending desire to implement 'clonable' modular facilities that can be delivered in a timely fashion across multiple locations. Companies like Merck KGaA, Darmstadt, Germany and G-CON Manufacturing are working together to combine their technologies and develop simple yet robust platform solutions for industry.
As bioprocessing technologies intensify performance, volumetric requirements become less. As such, 2000L single-use bioreactors - or multiple bioreactors of similar or less volumes - now suffice for the production of novel or biosimilar recombinant proteins. Such a shift in the industry enables the development of more mobile, modular facility designs. We will describe the rationale for this collaboration and its result: a turn-key solution that integrates a templated process train with a rapidly-deployable facility platform. By combining the unique advantages found with the G-CON POD construction and the bioprocess technology expertise from within Merck KGaA, Darmstadt, Germany, the goal of creating a cost-effective, pre-fabricated alternative to historical 'stick built' facilities is being achieved. Additionally, the flexibility inherent to our approach provides for a greater configurability that confers more user-specified choice into the selection of options. Simple in concept, this solution is also robust, cost-effective, and conducive to tight timelines for implementation.
In this webinar you will learn:
- Basic options for facilities/capacity expansion
- The value of templated process trains employing single-use equipment
- How modular, prefabricated PODs® outfitted with such single-use bioprocessing equipment represent an attractive, cost-effective strategy for capacity expansion
POD® is a registered trademark of G-CON Manufacturing, Inc.
In this presentation from IVT's GMP Week, Journal of Validation Technology Editor-in-Chief, Paul Pluta, Ph.D., asks "can compliance be improved by using quality by design [QbD] concepts?" Pluta discussed the QbD application, development of validation master plans, and the lifecycle approach to process validation. Furthermore, he discusses how to incorporate these essential parts of the validation process to implement effective, and efficient, compliance by design into the quality system.
Modern BioManufacturing: Single-Use Technologies in Configurable, Prefabricat...MilliporeSigma
A co-webinar describing a solution to biopharma's challenge of rapidly and rationally expanding capacity by employing single-use technologies, a templated process train, and pre-fabricated mobile/modular cleanrooms.
Biopharmaceutical companies on the verge of investing into manufacturing or facilities expansion face many questions and challenges. Speed, agility, and flexibility are becoming more critical to executing their changing production and distribution strategies. Platform facility designs which integrate the latest procss technologies wthin innovative pre-fabricated cleanrooms are critical for addressing the trending desire to implement 'clonable' modular facilities that can be delivered in a timely fashion across multiple locations. Companies like Merck KGaA, Darmstadt, Germany and G-CON Manufacturing are working together to combine their technologies and develop simple yet robust platform solutions for industry.
As bioprocessing technologies intensify performance, volumetric requirements become less. As such, 2000L single-use bioreactors - or multiple bioreactors of similar or less volumes - now suffice for the production of novel or biosimilar recombinant proteins. Such a shift in the industry enables the development of more mobile, modular facility designs. We will describe the rationale for this collaboration and its result: a turn-key solution that integrates a templated process train with a rapidly-deployable facility platform. By combining the unique advantages found with the G-CON POD construction and the bioprocess technology expertise from within Merck KGaA, Darmstadt, Germany, the goal of creating a cost-effective, pre-fabricated alternative to historical 'stick built' facilities is being achieved. Additionally, the flexibility inherent to our approach provides for a greater configurability that confers more user-specified choice into the selection of options. Simple in concept, this solution is also robust, cost-effective, and conducive to tight timelines for implementation.
In this webinar you will learn:
- Basic options for facilities/capacity expansion
- The value of templated process trains employing single-use equipment
- How modular, prefabricated PODs® outfitted with such single-use bioprocessing equipment represent an attractive, cost-effective strategy for capacity expansion
POD® is a registered trademark of G-CON Manufacturing, Inc.
In this presentation from IVT's GMP Week, Journal of Validation Technology Editor-in-Chief, Paul Pluta, Ph.D., asks "can compliance be improved by using quality by design [QbD] concepts?" Pluta discussed the QbD application, development of validation master plans, and the lifecycle approach to process validation. Furthermore, he discusses how to incorporate these essential parts of the validation process to implement effective, and efficient, compliance by design into the quality system.
Process Validation Presentation from BioTechLogicPeter Dellva
Exploring Manufacturing Process Validation - BioTechLogic, Inc. is a biopharmaceutical manufacturing and CMC consulting firm with strategic and practical/hands-on experience that helps clients bring their products to market quickly and successfully by augmenting and optimizing an organization’s technical, manufacturing, analytical, and regulatory resources.
Our technical expertise resides in a wide range of biological and oligonucleotide products including recombinant proteins, vaccines and blood products. Through the combined expertise and knowledge of our staff, we have developed proven methodologies and approaches for providing reliable and dependable services in the following areas:
Process Development and Quality by Design (QbD) including:
Design of Experiments (DOE)
Development Reports
Critical Process Parameter Evaluation
Technology Implementation, Transfer and Scale-up
On-site third party contract manufacturing support
BioAnalytical Services
Process Validation
Biotechnology Project Management
Quality Assurance
Regulatory Submissions
PAI Inspection Readiness (FDA Pre-Approval Inspection Readiness)
Are you involved with planning tech transfer of your drug product? Join this webinar to learn more about the regulations and considerations you need to consider and learnings from a case study.
According to ICH Q10, “The goal of technology transfer activities is to transfer product and process knowledge between development and manufacturing, and within or between manufacturing sites to achieve product realization. This knowledge forms the basis for the manufacturing process, control strategy, process validation approach, and ongoing continual improvement.”
As a result, there is an expectation for transfers to be performed in an organized, methodical manner with appropriate documentation. It is also expected that they happen between one Process Development group to another or to a Pilot Lab, from Process Development lab to clinical or commercial manufacturing, or from Process Development to external clinical manufacturing. Lastly, they may also happen between two company facilities at commercial scale, or between a company and an external contract manufacturing at commercial scale.
This presentation will cover points to consider for successful tech transfers with a focus on cGMP training requirements, and include lesson learned from real cases.
Presented by Guillaume Plane on September 22, 2016
This workshop examines the approach to Continued Process Verification and demonstrating that your product and process are operating in a state of control and continue to do so over the life of the product. Without any prior coordination, the theme was elaborated by the afternoon speakers once the conference itself was underway. The concept of “step up step down” for adjusting the level of product scrutiny both for process parameters monitoring and for sampling and testing quality attributes was explored and developed.
It is the part of the pharmaceutical industry where a lab scale formula is transformed into a viable product by development of liable and practical procedure of manufacture.
Process Validation Presentation from BioTechLogicPeter Dellva
Exploring Manufacturing Process Validation - BioTechLogic, Inc. is a biopharmaceutical manufacturing and CMC consulting firm with strategic and practical/hands-on experience that helps clients bring their products to market quickly and successfully by augmenting and optimizing an organization’s technical, manufacturing, analytical, and regulatory resources.
Our technical expertise resides in a wide range of biological and oligonucleotide products including recombinant proteins, vaccines and blood products. Through the combined expertise and knowledge of our staff, we have developed proven methodologies and approaches for providing reliable and dependable services in the following areas:
Process Development and Quality by Design (QbD) including:
Design of Experiments (DOE)
Development Reports
Critical Process Parameter Evaluation
Technology Implementation, Transfer and Scale-up
On-site third party contract manufacturing support
BioAnalytical Services
Process Validation
Biotechnology Project Management
Quality Assurance
Regulatory Submissions
PAI Inspection Readiness (FDA Pre-Approval Inspection Readiness)
Are you involved with planning tech transfer of your drug product? Join this webinar to learn more about the regulations and considerations you need to consider and learnings from a case study.
According to ICH Q10, “The goal of technology transfer activities is to transfer product and process knowledge between development and manufacturing, and within or between manufacturing sites to achieve product realization. This knowledge forms the basis for the manufacturing process, control strategy, process validation approach, and ongoing continual improvement.”
As a result, there is an expectation for transfers to be performed in an organized, methodical manner with appropriate documentation. It is also expected that they happen between one Process Development group to another or to a Pilot Lab, from Process Development lab to clinical or commercial manufacturing, or from Process Development to external clinical manufacturing. Lastly, they may also happen between two company facilities at commercial scale, or between a company and an external contract manufacturing at commercial scale.
This presentation will cover points to consider for successful tech transfers with a focus on cGMP training requirements, and include lesson learned from real cases.
Presented by Guillaume Plane on September 22, 2016
This workshop examines the approach to Continued Process Verification and demonstrating that your product and process are operating in a state of control and continue to do so over the life of the product. Without any prior coordination, the theme was elaborated by the afternoon speakers once the conference itself was underway. The concept of “step up step down” for adjusting the level of product scrutiny both for process parameters monitoring and for sampling and testing quality attributes was explored and developed.
It is the part of the pharmaceutical industry where a lab scale formula is transformed into a viable product by development of liable and practical procedure of manufacture.
Anteprima Pianificazione strategica per gli studi professionali della Guida a...eAgisco
L'anteprima del Modulo che ti proponiamo oggi è dedicato alla "Pianificazione strategica per gli studi professionali" dove vengono presi in esame il processo di elaborazione dei piani strategici e le modalità con cui essi vengono messi in atto all'interno dello studio, alla luce della tipologia di attività svolta e del mercato in cui si opera.
First of a two-part article published in Pharmaceutical Technology magazine in December 2005.
Part 1 describes facility and equipment design review, validation project organization and planning, and validation master plan development.
PAT and QbD concepts in designing the LiMS and other Electronic systems in La...balakrishna t
tQmlab® is the premier management system for GxP operations and for supporting regulatory submissions. It delivers transformational productivity for QA/QC labs supporting customised workflows for quality control of drugs, stability testing, product release testing and post-release quality testing.
Process Validation is Key important factor for the Pharmaceutical Industry to maintain Consistent Quality in product which claimed by the manufacturer.
009 what are the systems validation protocol methods at atl 05 28-2015atlmarketing
If your product must meet the requirements of FDA cGMP, 21 CFR 210, 211, 820, ISO-9000, ISO-13485, or MDD/93/42/EEC (for the CE Mark), there are three very critical elements you must have to be in regulatory compliance. First, you must have a sound and strong Quality Management System (QMS). This is an expression of WHAT you do (your quality policies and structure). Second, you must have reliable Standard Operating Procedures (SOP’s). These are expressions of HOW YOU DO THINGS.
Missing in the above two items is an expression of HOW WELL YOU DO WHAT YOU DO? This is where you must establish your “Systems Validation Protocol” (SVP). Your SVP is an expression of how well your system is working (for example, this can be expressed in overall product conformance percentage or in defects per million for your various products). The SVP is a living and continuous document based on your quality records. The ATL White Paper “What Are The Systems Validation Protocol Methods At ATL?” is our attempt to share with you a sound approach to Systems Validation and the various protocols that you can use.
Quality Assurance is of Tremendous Importance in Pharma and Health care sector.
A brief of that is try to explain here..
A Trust of the Customer on Product is solely based on the Effective QA
1. BUSINESS REQUIREMENTS
Manages the Prevents Enforces Automates Maintains
procurement of unsafe compliance to work production
raw materials products from regulatory processes for equipment and
needed for entering the requirements Quality machinery by
manufacturing supply chain, throughout the Management, scheduling work
as well as track manufacturing Projects, R&D, and shutdowns,
and monitor processes, manufacturing procuring
individual beginning with laboratories … maintenance
product units order release supplies and
and material managing spare
availability parts inventory
check, to
manufacturing
and packaging
Copyright New Strategies 2011
1
2. MODULES AX for Pharma Modules
Advanced Quality GMP Plant
Basic Pharma (BPH)
Management (AQM) Maintenance (GPM)
Activity Based Product
Dispensing (DIS)
Costing (COS)
Microsoft Dynamics AX Process Industries Modules
Manufacturing Distribution
Microsoft Dynamics AX Main Modules
Manufacturing Project Accounting Distribution
Human Resource Financial
Enterprise Portal
Management Management
Customer Relationship Supply Chain
Business Analysis
Management Management
Copyright New Strategies 2011
2
3. INDUSTRY CHALLENGES 1/3
Area Industry Challenge GxP
Item master Creation of a new item card with multiple approval steps and item √
usage restriction according to approval status
Sales Secure delivery of items approved by the customer in agreement √
with country regulations and customer specifications
Shipments Customer/item specific Certificate of Analysis, covering customer √
quality standards and country regulatory requirements
Purchasing Regulated material can be purchased only from approved vendors √
and after the completion of vendor audit and qualification
Production Production operations needs to be stopped in case of out of specs √
results during in process controls
Production Batch and expiry dates are calculated according to the intermediate √
product dates
Production Rework and reprocess orders with restriction of allowed operations √
and ingredients depending on order type
Copyright New Strategies 2011
3
4. INDUSTRY CHALLENGES 2/3
Area Industry Challenge GxP
Production Management of Master Batch Record √
QC Compliancy to statutory and regulatory requirements: √
1. Definition of internal and external specifications
2. Number of replications required
3. Statistical approach to testing (reduced testing/skip testing)
4. Test criteria
5. Sampling plans
6. Specifications approval process
QA/QC Possibility to manage QC and QA reports within the system √
QC QC quality order approval workflow different by item/item type with √
multiple levels of approval as required by GxP
Batch release QA review of analytical batch record and QP approval for the release √
of finished product to the customer
Lot 1. Restriction of changes of batch status allowed by role, following √
traceability the risk based approach of GAMP 5.
2. Verification of batch history and approval status of all
components of a manufactured product.
Copyright New Strategies 2011
4
5. INDUSTRY CHALLENGES 3/3
Area Industry Challenge GxP
Potency/ Calculation of Assay of APIs, Recalculation of Reservations, √
Dispensing Dispensing
Stability Management of Stability Studies, Cost of Quality √
Studies
Plant Management of GMP critical maintenance activities (e.g. cleaning, √
Maintenance calibration etc.) for laboratory equipment
Plant Possibility to manage preventive and corrective maintenance for √
Maintenance machinery and equipment
Plant Management of spare parts √
Maintenance
Plant Full traceability of the maintenance activities for each √
Maintenance machineryequipment
Documentation Documentation and Validation Methodology √
and Validation
Copyright New Strategies 2011
5
6. THE ADVANTAGES OF AN INTEGRATED ERP SOLUTION FOR THE
PHARMACEUTICAL INDUSTRY
AX for Pharma 2012
Is fully compliant to EMA, US, and LATAM regulatory requirements (e.g.
FDA)
Enforces operating procedures (e.g. GxP) and work practices
Integrates or interfaces LIMS, Dispensing and Plant Maintenance
functionality
Integrates laboratory data and plant maintenance activities with the rest of
the business
Allows ERP users easily access to data (e.g. from laboratory and
maintenance) for reporting, result trending, workload assessment etc.
Reduces the TCO of the ERP system
Is a robust and adaptive platform
Supports a wide range of workflows (e.g. item approval, purchase order,
quality order etc.)
Copyright New Strategies 2011
6
7. APPROACH
Our approach to enterprise solution architecture, design, development, integration
and validation significantly reduces implementation costs and enables companies to
work with a single implementation team, ensuring consistency, bringing savings and
achieving compliancy. These aspects, always important, become critical when the
validation of an extended ERP solution is required.
Working with carefully selected global partners, we help our partners and customers
understand their vertical and business needs and then provide the right solution fit,
while minimizing customizations and streamlining implementations
Copyright New Strategies 2011
7